Results 261 to 270 of about 146,874 (392)

Treatment Outcomes of HER2-Directed Therapy in Patients With HER2-Positive Non-metastatic Breast Cancer in Low-Resource Settings. [PDF]

Cureus
Imran M, Majeed MA, Bin Naeem S, Jamil MA, Shahzad M, Akhtar F, Karim A, Ahmad A, Bano S, Aqib B, Abdullah Javaid Bukhari S.   +10 more
europepmc   +1 more source

Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells [PDF]

, 2017
et al,, Ghasemi, Reza
core   +2 more sources

Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2‐Low Breast Cancer With Cancer‐Related Microangiopathic Hemolytic Anemia: A Case Report

Cancer Innovation, Volume 4, Issue 5, October 2025.
The diagnosis and treatment of acquired hemolytic anemia can be challenging. In breast cancer patients, it may be directly associated with the underlying malignancy (as an initial presentation or during disease progression). The diagnosis of cancer‐related microangiopathic hemolytic anemia (CR‐MAHA) is often delayed, and patients have a high mortality ...
Mengyuan Li, Mao Ding, Yukun Hou, Xuening Duan, Yuanjia Cheng, Ling Xu   +5 more
wiley   +1 more source

Reply to the article “A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model based cost-effectiveness analysis”, by J. Norum et al. (Ann Oncol 2005; 16: 909–914) [PDF]

, 2005
M.-E. Bonneterre, Jacques Bonneterre
openalex   +1 more source

HER2/neu as a Signaling and Therapeutic Marker in Uterine Serous Carcinoma. [PDF]

Cells
Ettorre VM, Palmieri L, Clemente V, Santin AD.   +3 more
europepmc   +1 more source

Comprehensive Genomic Profiling in Advanced Non‐Small Cell Lung Cancer: A Real‐World Cohort Study in Finland

Cancer Medicine, Volume 14, Issue 19, October 2025.
ABSTRACT Background Non‐small cell lung cancer (NSCLC) is a disease with a low survival rate and poor prognosis. Targeted therapies have improved treatment outcomes as driver mutations have been identified, especially in adenocarcinomas. Comprehensive genomic profiling (CGP) provides insights into the genetic mutation profile of cancer and helps ...
Kirsi Hormalainen, Kaisa Marttila, Matti Nykter, Toomas Uibu, Jarkko Ahvonen, Vidal Fey, Mauri Keinänen, Maarit Bärlund, Arja Jukkola   +8 more
wiley   +1 more source

Cardiac issues related to trastuzumab

, 2004
Edith A. Perez
openalex   +1 more source

Adjuvant trastuzumab for breast cancer: Advent of pharmacogenetics raises many issues [PDF]

, 2005
Hazel Thornton
openalex   +1 more source

Case of Relapsed, Metastatic Cutaneous Squamous Cell Carcinoma With HER2 Mutation Treated With Trastuzumab. [PDF]

Clin Case Rep
Kye Y, Marshalek J, Wise D, Peng S, Hwang A.   +4 more
europepmc   +1 more source

An Evaluation of HER2 Expression Heterogeneity in Primary Tumors and Metastatic Lymph Nodes of Patients With Advanced Extramammary Paget's Disease: Prognostic and Therapeutic Implications

Cancer Medicine, Volume 14, Issue 19, October 2025.
ABSTRACT Background HER2 expression in primary versus metastatic tumors in advanced Extramammary Paget's Disease (EMPD) remains inadequately characterized. This investigation aimed to assess HER2 expression heterogeneity between primary tumors and metastatic lymph nodes (LNs) in patients with advanced EMPD and to assess the prognostic value of HER2 ...
Zhicheng Liu, Xingliang Tan, Zhiming Wu, Yi Tang, Qianghua Zhou, Wensu Wei, Cong Yang, Long Huang, Yanjun Wang, Kai Yao   +9 more
wiley   +1 more source